72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study-Reference-Cited by-同舟云学术

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Published:2022-08 Issue:8 Volume:9 Page:e534-e543
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Malaba Thokozile R,Nakatudde Irene,Kintu Kenneth,Colbers Angela,Chen Tao,Reynolds Helen,Read Lucy,Read Jim,Stemmet Lee-Ann,Mrubata Megan,Byrne Kelly,Seden Kay,Twimukye Adelline,Theunissen Helene,Hodel Eva Maria,Chiong Justin,Hu Nai-Chung,Burger David,Wang Duolao,Byamugisha Josaphat,Alhassan Yussif,Bokako Sharon,Waitt Catriona,Taegtmeyer Miriam,Orrell Catherine,Lamorde Mohammed,Myer Landon,Khoo Saye,Boffito Marta,Clayden Polly,Peto Tim,Pozniak Anton,Taylor Graham,Kambugu Andrew,Ayabo Tabitha,Kitaka Sabrina Bakeera,Byakika-Kibwika Pauline,Kiiza Daniel,Kyohairwe Isabella,Laker Eva,Luswata Andrew,Magoola Johnson,Mayanja Hamza,Najujuma Flavia Vivian,Nakijoba Ritah,Namuddu Diana,Namuli Teopista,Ntuyo Peter,Onzia Annet,Sempijja Emmanuel,Tabwenda Jovia,William Baluku,Abrahams Nina,Magano Phakamani,Delport Carmen,Hlwaya Linda,Mehta Ushma,Molitsane Dineo,Odayar Jasantha,Tambula Sivuyile,Tyam Mbuviswa,Venfolo Olga,Allerton Joanna,Nkonyana Thozama,Mqaba Sibongile,Else Laura,Potter Steve,Neary Anne

Funder

ViiV Healthcare

Gilead UK and Ireland Corporate Contributions

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference24 articles.

1. Early initiation of ARV during pregnancy to move towards virtual elimination of mother-to-child-transmission of HIV-1 in Yunnan, China;Meyers;PLoS One,2015

2. Update of recommendations on first- and second-line antiretroviral regimens. 2019. World Health Organization,2019

3. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial;Kintu;Lancet HIV,2020

4. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

5. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool;Gallagher;PLoS One,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda;Value in Health Regional Issues;2024-11

2. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study;BMC Infectious Diseases;2024-09-02

3. Advances in HIV Management During Pregnancy and Infant Feeding;Infectious Disease Clinics of North America;2024-09

4. Pharmacokinetics of drugs used to treat drug sensitive-tuberculosis in breastfeeding mother-infant pairs: An observational pharmacokinetic study;Wellcome Open Research;2024-08-12

5. Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa;Journal of Antimicrobial Chemotherapy;2024-07-13